Trial · NCT05981742
Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS
NCT05981742, Phase 2, Completed, Al-Rasheed University College
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS. Trials, record NCT05981742. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05981742
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS
- NCT number
- NCT05981742
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 75 participants, actual
- Lead sponsor
- Al-Rasheed University College
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Metformin Hydrochloride 500 MG, Cabergoline 0.5 MG, Metformin Hydrochloride 500 MG + Cabergoline 0.5 MG
- First posted
- 2023-08-08
- Last updated
- 2023-08-08
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Body Mass Index (BMI) | at Baseline, and after 90 days | Measured in Kg/m² as a part of hormone status changes analysis |
| Primary | Serum Anti-Müllerian hormone (AMH) | at Baseline, and after 90 days | Measured in ng/mL as a part of hormone status changes analysis |
| Primary | Serum Testosterone | at Baseline, and after 90 days | Measured in ng/mL as a part of hormone status changes analysis |
| Primary | Serum Luteinizing hormone (LH) | at Baseline, and after 90 days | Measured in mIU/mL as a part of hormone status changes analysis |
| Primary | Serum Follicular Stimulating Hormone (FSH) | at Baseline, and after 90 days | Measured in mIU/mL as a part of hormone status changes analysis |
| Primary | Serum Prolactin (PRL) | at Baseline, and after 90 days | Measured in ng/mL as a part of hormone status changes analysis |
| Primary | Mean number of dominant follicles (DF) | at Baseline, and after 90 days | Calculated by ultrasonography as a part of the ultrasonic analysis |
| Primary | Mean Resistive Index (RI) | at Baseline, and after 90 days | Calculated by ultrasonography as a part of the ultrasonic analysis |
| Primary | Serum Anti-GAD antibody | at Baseline, and after 90 days | Measured in ng/mL as a part of inflammatory markers analysis |
| Primary | Serum Anti-GnRH antibody | at Baseline, and after 90 days | Measured in pg/mL as a part of inflammatory markers analysis |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05981742
GET https://conductscience.org/api/trials/v1/NCT05981742/registered